Marie-Paule Sablin - Department of Drug Development and Innovation (D3i), Institut Curie

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 151 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

CLINICAL CANCER RESEARCHno. 4 (2024): 767-778

Cited11Views0WOSBibtex

The Impact of Targeted Therapies on Molecular Alterations Identified by an Institutional Molecular Tumor Board: an Approach Based on ESCAT Classification

K. Rahmani Narj Abadi,C. Dupain, I. Guillou, R. Sanchez, K. Nedara,G. Marret,S. Hescot,M-P. Sablin, Z. Castel-Ajgal,C. Neuzillet,E. Borcoman,D. Bello Roufai, M. Rodrigues, A. Asnacios Lecerf,C. Callens, O. Trabelsi-Grati,S. Melaabi,K. Driouch, S. Antonio, E. Lemaitre

ESMO Real World Data and Digital Oncology (2024): 100092

Cited0Views0Bibtex

Fulvestrant and Everolimus Efficacy after CDK4/6 Inhibitor: a Prospective Study with Circulating Tumor DNA Analysis

Antoine Vasseur,Luc Cabel,Caroline Hego, Wissam Takka,Olfa Trabelsi Grati,Benjamin Renouf,Florence Lerebours,Delphine Loirat,Etienne Brain,Paul Cottu,Marie-Paule Sablin,Jean-Yves Pierga,Céline Callens,Shufang Renault,François-Clément Bidard

ONCOGENE（2024）

Cited1Views0WOSNATUREBibtex

Supplementary Tables and Figures 1 from First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Peter Schmid, Nicholas C. Turner,Carlos H. Barrios,Steven J. Isakoff,Sung-Bae Kim,Marie-Paule Sablin,Shigehira Saji,Peter Savas,Gregory A. Vidal,Mafalda Oliveira,Joyce O'Shaughnessy,Antoine Italiano,Enrique Espinosa,Valentina Boni,Shane White,Beatriz Rojas,Ruffo Freitas-Junior,Yeesoo Chae,Igor Bondarenko,Jieun Lee, Cesar Torres Mattos, Jorge Luis Martinez Rodriguez,Lisa H. Lam,Surai Jones,Sarah-Jayne Reilly, Xiayu Huang,Kalpit Shah,Rebecca Dent

openalex（2024）

Cited0Views0Bibtex

319Tip NeoBREASTIM: A Phase II Study of Atezolizumab Plus RP1 Oncolytic Immunotherapy in the Neoadjuvant Setting of Triple-Negative Breast Cancer (TNBC)

E. Bastien, B. Grandal, R. Sanchez,T. Ramtohul,D. Loirat,M.P. Sablin,A. Vincent-Salomon,J-Y. Pierga,F.C. Bidard,C. Malhaire,A. Savignoni,E. Romano

Annals of Oncology (2024): S347-S348

Cited0Views0Bibtex

138P Precision Medicine Phase II Study Evaluating the Efficacy of Olaparib in Patients with Progressive Solid Cancers and Carriers of Homologous Recombination Repair Genes Alterations

M. Polito,C. Le Tourneau,A. DeMontfort,S. Cousin,M. Toulmonde,C. A. Gomez-Roca,K. Bourcier,I. Korakis,F. Bertucci,E. Mitry, C. Mazza,P. Cassier,C. Coutzac,A. Italiano,V. K. Attignon, R. Mayet,D. Perol,M. P. Sablin,J. Y. Blay,O. Tredan

ANNALS OF ONCOLOGY (2023): S236-S236

Cited1Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn